Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2016 Aug 11;128(6):877-80.
doi: 10.1182/blood-2016-03-705012. Epub 2016 Jun 20.

Complete remission in a patient with JAK2- and IDH2-positive myelofibrosis

Lucia Masarova  1 , Wei Wang  2 , Kate J Newberry  1 , Hagop Kantarjian  1 , Srdan Verstovsek  1
Affiliations
Case Reports

Complete remission in a patient with JAK2- and IDH2-positive myelofibrosis

Lucia Masarova et al. Blood. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Change in clinical parameters with time on ruxolitinib. Spleen and bone marrow (A), hematologic (B), and molecular and cytogenetic (C) responses over time.
Figure 2
Figure 2
Histomorphologic assessment of bone marrow core biopsy samples. (A) Bone marrow before therapy. Bone marrow after 24 months (B) and after 88 months (C) on therapy. Hematoxylin and eosin staining, original magnification ×500.
See this image and copyright information in PMC

References

    1. Mesa RA, Niblack J, Wadleigh M, et al. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. Cancer. 2007;109(1):68–76. - PubMed
    1. Ballen KK, Shrestha S, Sobocinski KA, et al. Outcome of transplantation for myelofibrosis. Biol Blood Marrow Transplant. 2010;16(3):358–367. - PMC - PubMed
    1. Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010;363(12):1117–1127. - PMC - PubMed
    1. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366(9):799–807. - PMC - PubMed
    1. Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366(9):787–798. - PubMed